



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

### **GENEGO RELEASES CONTENT AND TOOLS FROM INDUSTRY-FDA DRIVEN METATOX PARTNERSHIP VIA TOXHUNTER™**

**St. Joseph, Michigan, March 8<sup>th</sup> 2010** – GeneGo announces the release of the first set of tools and content to come out of its industry-FDA MetaTox™ partnership program. The MetaTox partnership is developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D.

ToxHunter will be made available as an add-on to existing licenses of GeneGo's MetaCore™ and/or MetaDrug™ systems biology and systems pharmacology platforms.

ToxHunter includes a unique, detailed ontology of compound-induced pathological observations covering 7 target organs in the initial release, as well as a comprehensive, manually-curated knowledgebase of gene, protein, metabolite, and chemical associations to pathology terms that is searchable by pathology, toxicant, or gene, protein & metabolite biomarkers. ToxHunter also enables new experimental analysis and visualization tools such as an exclusive enrichment module for identifying specific gene-pathology associations, and a suite of new toxicity-focused pathway maps and QSAR models.

"It is immensely exciting to see the ideas and input of the MetaTox partnership come to fruition through the hard-work and dedication of the GeneGo team," said Richard Brennan, Director of Toxicology at GeneGo. "This initial release provides the community with a unique and powerful set of tools to help make sense of the flood of molecular data being generated by modern safety assessment groups. The next 12-18 months will see a further expansion of the capability of the platform as more of the tools developed by the partnership are released."

"It is very important to GeneGo and our end users that we build these tools and content in collaboration with partners as they know exactly what they need and what is currently missing in the marketplace," said Julie Bryant, VP Business Development. "We truly believe we have delivered important productivity tools to the tox field based on the extremely positive feedback we have already received from ToxHunter demonstrations."

GeneGo will be demonstrating ToxHunter at the annual meeting of the Society of Toxicology in Salt Lake City, Utah, this week (booth #1937, March 7-11), and is offering a 50% discount on the full price to anyone who licenses this new ToxHunter prior to release (offer good through June 30<sup>th</sup>, 2010 with a signed purchase agreement and payment).

**About GeneGo, Inc.**

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.1™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

**ToxHunter™, MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.**